Atlas market file · Equity · United States
Liminatus Pharma, Inc.LIMN
- Last close
- 0.0989
- Change
- -5.81%
- 96-bar range
- 0.095 – 0.358
- As of
- 6 Aug 2026
Liminatus Pharma, Inc. is a biological products, (no diagnostic substances) issuer listed as LIMN on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
LIMN
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 68 weekly closes (-98.77% over the window).
Source rail: Yahoo Finance chart API (LIMN). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for LIMN. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
LIMN public profile
Biological products, (no diagnostic substances) issuer. Liminatus Pharma, Inc. is connected to current market context, cited company sources and its retained research file.
Liminatus Pharma, Inc. trades as LIMN on NASDAQ. Liminatus Pharma, Inc. (LIMN) has a latest verified close of 0.0989, down 5.81%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files LIMN under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Liminatus Pharma, Inc. today
Liminatus Pharma, Inc. has been in the news lately, with an Amended and Restated Merger Agreement announced on June 29, 2026. However, the company's financials tell a different story, with a net income loss of $1.1 million and operating income loss of $1.1 million for the period ending 2026-03-31.
The company's research and development expenses of $400,000 for the same period raise questions about their allocation of resources. Liminatus Pharma, Inc. is a pharmaceutical company, and their products and pipeline are crucial to their financial success.
According to their latest 10-Q filing, the company's assets stand at $2.8 million, while their liabilities are $2.9 million. The company's stockholders' equity attributable to parent is -$132,596, which is a cause for concern. The company's recent filings, including the SCHEDULE 13G and 8-K, provide more insight into their financial situation.
The company's chart and market mechanism are also worth examining. With a weighted average number of shares outstanding, diluted, of 36.0 million shares, the company's share price and trading volume are crucial to their market success.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
LIMN technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on LIMN
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep LIMN research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
LIMN FAQ
What is Liminatus Pharma, Inc. (LIMN)?Liminatus Pharma, Inc. (LIMN) has a latest verified close of 0.0989, down 5.81%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Liminatus Pharma, Inc. (LIMN) has a latest verified close of 0.0989, down 5.81%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for LIMN?Liminatus Pharma, Inc. (LIMN) has a latest verified close of 0.0989, down 5.81%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources,...
Liminatus Pharma, Inc. (LIMN) has a latest verified close of 0.0989, down 5.81%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files LIMN under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the LIMN page updated?The LIMN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The LIMN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for LIMN?The LIMN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:LIMN. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The LIMN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:LIMN. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on LIMN?Yes. The workstation can open LIMN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open LIMN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this LIMN page investment advice?No. The LIMN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The LIMN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →